Effects of carperitide (.ALPHA.-human atrial natriuretic peptide) on acute congestive heart failure in dogs
| Autor: | T, Hidaka, K, Aisaka, T, Ohno, T, Ishihara |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Male
medicine.medical_specialty Cardiac output medicine.medical_treatment Hemodynamics Urine Electrolytes Nitroglycerin Dogs Oxygen Consumption Atrial natriuretic peptide Furosemide Internal medicine medicine Animals Humans Heart Failure Pharmacology Dose-Response Relationship Drug business.industry Myocardium Hydralazine medicine.disease Peptide Fragments Disease Models Animal Heart failure Cardiology Female Dobutamine Diuretic business Atrial Natriuretic Factor medicine.drug |
| Zdroj: | Folia Pharmacologica Japonica. 101:233-251 |
| ISSN: | 1347-8397 0015-5691 |
| DOI: | 10.1254/fpj.101.4_233 |
| Popis: | Effects of carperitide (alpha-human atrial natriuretic peptide) on hemodynamics and renal function in dogs with congestive heart failure (CHF) produced by volume expansion and ligation of the left anterior descending coronary artery were compared with those of various anti-heart failure agents (cardiotonic, vasodilator and diuretic). Carperitide (0.1-1 microgram/kg/min) dose-dependently decreased the elevated left ventricular end-diastolic pressure (LVEDP). No significant changes in cardiac contractility (LV dP/dtmax) and heart rate (HR) were noted, although cardiac output (CO) tended to reduce during the infusion of carperitide. Nitroglycerin (NG; 3 micrograms/kg/min) and furosemide (1 mg/kg) also decreased LVEDP, but the potency was less than that of carperitide. Sodium nitroprusside (SNP; 10 micrograms/kg/min) and dobutamine (10 micrograms/kg/min) caused a reduction in LVEDP and increased CO with an increase in HR. Hydralazine (H; 100 micrograms/kg/min) increased CO without reduction in LVEDP and induced a pronounced increase in HR. Double product (systolic blood pressure x HR), an index of myocardial oxygen consumption, was significantly reduced by carperitide, but significantly increased by DB and H. Carperitide, unlike NG, SNP, H and DB, increased urine volume and urinary electrolyte excretion. These results suggest that carperitide will be an useful therapeutic agent for the treatment of CHF. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|